Pharmaceutical composition for preventing or treating bone diseases
N-dodecyl-4-hydroxybenzamide-based compositions inhibit osteoclast differentiation and activity, addressing the limitations of current osteoporosis treatments by providing a safer and more effective therapeutic option.
Patent Information
- Application Number
- KR1020250058134
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-02
- Publication Date
- 2026-11-10
AI Technical Summary
Current drug therapies for bone diseases such as osteoporosis have limitations due to side effects and lack of verified efficacy, necessitating the development of safer and more effective treatments that target osteoclasts selectively.
A pharmaceutical composition containing N-dodecyl-4-hydroxybenzamide, its pharmaceutically acceptable salts, hydrates, or solvates, which inhibits osteoclast differentiation and activity, thereby preventing or treating bone diseases like osteoporosis.
The composition effectively inhibits osteoclast differentiation and activity, offering potential therapeutic benefits for osteoporosis by reducing the expression of key genes associated with osteoclast function, thus preventing or treating the disease.
Smart Images

Figure PAT00009_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases. Background Technology
[0002] Bone is a dynamic tissue that undergoes continuous removal and reconstruction through bone resorption and formation. This process is carried out by two types of cells: osteoclasts and osteoblasts. Specifically, osteoblasts are responsible for bone formation, while osteoclasts are responsible for bone removal. Under normal conditions, bone homeostasis is maintained through the balanced activity of these two types of cells. However, homeostasis can be disrupted by the abnormal overactivity of these two types of cells, particularly osteoclasts, resulting in bone diseases such as osteoporosis, periprosthetic osteolysis, and Paget's disease. The aforementioned osteoclasts are multinucleated cells differentiated from the macrophage lineage that induce bone resorption, thereby causing osteoporosis. Therefore, the precise regulation of osteoclast differentiation and function is a critical aspect in the prevention and treatment of bone diseases, including osteoporosis.
[0003] RANKL (receptor activator of nuclear factor-kB ligand) is required for differentiation into these osteoclasts, and M-CSF (macrophage colony stimulating factor) is required for the proliferation of osteoclast precursor cells. Osteoclast differentiation begins when RANKL binds to its receptor, RANK. When RANKL binds to RANK, adapter molecules such as TRAF (tumor necrosis factor receptor associated factor) are activated. TRAF2, TRAF5, and TRAF6, known as members of the TRAF family, activate transcription factors such as NF-kB and AP-1 (activator protein-1) that are necessary for osteoclast differentiation. When TRAF is activated by RANKL signaling for osteoclast differentiation, PI3K, TAK1 (transforming growth factor β-activated kinase), Akt / PKB, and MAPKs including JNK, ERK, and p38, as well as NF-kB, c-Fos, Fra-1, CREB (cyclic-AMP-responsive-element-binding protein), and NFATc1 (nuclear factor of activated T cells cytoplasmic 1), are activated. This induction occurs via the c-Fos pathway through TRAF6-NF-kB and RANKL-RANK signaling. Consequently, osteoclast-specific genes necessary for differentiation into osteoclasts, such as cathepsin K, TRAP (tartrate-resistant acid phosphatase), c-Fos, calcitonin receptor, OSCAR (osteoclast-associated receptor), c-Src, and NFATc1, are expressed.
[0004] Meanwhile, drug therapies for treating osteoporosis include drugs that promote bone formation or inhibit bone resorption to prevent a decrease in bone mass or increase bone mass, such as calcium preparations, vitamin D preparations, bisphosphonate preparations, estrogen agonists / antagonists, estrogen preparations, and teriparatide injection, a parathyroid hormone preparation, as a bone formation promoter. However, their actual efficacy has not yet been verified, and there are limitations to using them as effective treatments due to problems such as side effects from long-term use.
[0005] Therefore, there is a continuously growing need for safer and more effective new therapeutic agents for the prevention or treatment of bone diseases. Recently, the development of treatments for bone diseases using novel pharmacological substances based on natural products, synthetic compounds, peptides, or proteins has been actively pursued, and among these, there is particularly high interest in substances that can fundamentally demonstrate therapeutic effects by acting selectively on osteoclasts. Prior art literature
[0006] Korean Registered Patent No. 10-1990004 The problem to be solved
[0007] Accordingly, the inventors of the present invention have completed the present invention by identifying that, as a result of diligent research efforts to develop a safe and effective treatment substance for bone diseases, the N-dodecyl-4-hydroxybenzamide of the present invention has an excellent effect on inhibiting differentiation and activity into osteoclasts when treated with bone marrow cells, and can be usefully utilized in the treatment of bone diseases through its efficacy in excellently inhibiting the expression of various genes involved in the function of osteoclasts.
[0008] Accordingly, one objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of bone diseases.
[0009] In addition, another objective of the present invention is to provide a food composition for the prevention or improvement of bone diseases.
[0010] In addition, another objective of the present invention is to provide a veterinary composition for the prevention or treatment of bone diseases.
[0011] In addition, another objective of the present invention is to provide a feed composition for the prevention or improvement of bone diseases.
[0012] In addition, another objective of the present invention is to provide a culture medium composition for inhibiting the differentiation of osteoclasts. means of solving the problem
[0014] The terms used in this specification are for illustrative purposes only and should not be interpreted as being limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as "comprising" or "having" are intended to indicate the existence of the features, numbers, steps, actions, components, parts, or combinations thereof described in the specification, and should be understood as not precluding the existence or addition of one or more other features, numbers, steps, actions, components, parts, or combinations thereof.
[0015] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as generally understood by those skilled in the art to which the embodiments pertain. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and should not be interpreted in an ideal or overly formal sense unless explicitly defined in this application.
[0017] The present invention will be described in more detail below.
[0019] According to one aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of bone disease comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof:
[0020] [Chemical Formula 1]
[0021] .
[0022] The compound represented by the above chemical formula 1 of the present invention is a compound having the IUPAC name N-dodecyl-4-hydroxybenzamide (CAS Number 146501-46-4).
[0023] Although research on the specific pharmacological activity of the above compound is still ongoing, it has not been determined whether it has a direct preventive and therapeutic effect on bone diseases (preferably osteoporosis). In the present invention, it was first discovered that N-dodecyl-4-hydroxybenzamide, a compound represented by Chemical Formula 1, has an excellent therapeutic effect in mice with induced osteoporosis as a new use.
[0024] The above bone disease may include any bone disease known in the art, provided that the compound represented by Formula 1 of the present invention, its pharmaceutically acceptable salt, its hydrate, or its solvate exerts the desired effect, and may be, for example, one or more selected from the group consisting of osteoporosis, periprosthetic osteolysis, osteolysis caused by fatigue residue of implants, Paget's disease, osteomalacia, rickets, osteopenia, calcium dysregulation, metastatic bone cancer, inflammatory bone loss, endocrine disease or drug-induced secondary bone loss, and periodontal disease accompanied by destruction of alveolar bone, and preferably osteoporosis, but is not limited thereto.
[0025] The compound of Formula 1 contained as an active ingredient in the pharmaceutical composition of the present invention may exist in the form of a pharmaceutically acceptable salt.
[0026] The term "pharmaceuticalally acceptable salt" in this invention refers to any organic or inorganic addition salt of said compound at a concentration having a relatively non-toxic and harmless active effect on the patient, wherein the side effects caused by said salt do not impair the beneficial efficacy of said compound.
[0027] Acid addition salts are prepared by conventional methods, for example, by dissolving a compound in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, for example, methanol, ethanol, acetone, or acetonitrile. An equal molar amount of the compound and an acid or alcohol (e.g., glycol monomethyl ether) in water may be heated, and then the mixture may be dried by evaporation or the precipitated salt may be filtered by suction.
[0028] At this time, organic acids and inorganic acids may be used as free acids. Inorganic acids may include hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc., and organic acids may include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carboxylic acid, vanillic acid, hydroiodic acid, etc., but are not limited to these.
[0029] In addition, pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal salts or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium, or calcium salts as the metal salts, but is not limited to these. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).
[0030] Pharmaceutically acceptable salts of the compounds of the present invention comprise salts of acidic or basic groups that may be present in said compounds, unless otherwise indicated. For example, pharmaceutically acceptable salts may include sodium, calcium, and potassium salts of hydroxyl groups, and other pharmaceutically acceptable salts of amino groups include hydrobromide, sulfate, hydrosulfate, phosphate, hydrophosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), and p-toluenesulfonate (tosylate) salts, and may be prepared through methods for preparing salts known in the art.
[0031] In addition, the above compound comprises, without limitation, solvates such as its pharmaceutically acceptable salts as well as possible hydrates that can be prepared therefrom. Solvents of the above compound may be prepared using methods known in the art.
[0032] Furthermore, the above-mentioned compound may be prepared in a crystalline or amorphous form, and if prepared in a crystalline form, it may be optionally hydrated or solvated. The present invention may include not only stoichiometric hydrates of the above-mentioned compound but also compounds containing varying amounts of water. The solvates of the above-mentioned compound according to the present invention include both stoichiometric solvates and non-stoichiometric solvates.
[0033] Meanwhile, the method of obtaining N-dodecyl-4-hydroxybenzamide or a pharmaceutically acceptable salt thereof used in the pharmaceutical composition of the present invention is not particularly limited, and may be chemically synthesized by a method known in the art or commercially available materials may be used.
[0034] The term "osteoporosis" in this invention refers to a disease in which bone mass decreases due to various causes and the risk of fracture continuously increases due to the degeneration of the microstructure of bone tissue. It occurs when the minerals (especially calcium) and matrix constituting the bone are reduced, and the balance of bone remodeling is disrupted, resulting in osteoclastosis being greater than osteoblastosis. While the interior of a normal bone forms a dense, mesh-like structure, in the case of osteoporosis, the gaps between structures widen and the microstructure thins and weakens, progressing to a state where the bone can easily fracture even from a minor impact. Currently, there is no known treatment method that can fundamentally suppress or delay the onset of osteoporosis itself while alleviating its symptoms.
[0035] For example, the pharmaceutical composition of the present invention inhibits the differentiation, generation, and / or activity of osteoclasts, which are causative cells of bone disease, preferably osteoporosis, and inhibits the expression of one or more selected from the group consisting of TRAP (tartrate-resistant acid phosphatase), c-Fos, NFATc1 (Nuclear Factor of Activated T cells, cytoplasmic 1), OSCAR (osteoclast-associated receptor), cathepsin K, and c-Src.
[0036] The above phenomena are major factors involved in the progression of osteoporosis, and since the pharmaceutical composition of the present invention can effectively suppress these phenomena, it can exert the effect of preventing osteoporosis, delaying its onset, and alleviating the symptoms caused by it.
[0037] In a specific embodiment of the present invention, it was confirmed that when N-dodecyl-4-hydroxybenzamide (LSW04), a compound of Formula 1 of the present invention, was treated to bone marrow cells, it excellently inhibited cell fusion and the expression of related genes, which are measures of differentiation into osteoclasts, compared to the control group (N-dodecyl-2-hydroxybenzamide (LSW03)).
[0038] This indicates that a composition comprising the compound of Formula 1 of the present invention, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof can exhibit excellent effects for the prevention or treatment of osteoporosis.
[0039] The term "prevention" in this invention refers to any act of suppressing or delaying the occurrence, spread, and recurrence of osteoporosis by administering the pharmaceutical composition of this invention, and the term "treatment" refers to any act of improving or beneficially altering the symptoms of the said disease by administering the pharmaceutical composition of this invention.
[0040] In a specific embodiment of the present invention, the treatment may mean, but is not limited to, a reduction or alleviation of signs of osteoporosis, a reduction in the severity of the disease, a delay or slowing of the disease, a temporary palliation or stabilization of the disease state, and other beneficial results.
[0041] The term "individual" in this invention refers to an individual suspected of having osteoporosis, having developed or being susceptible to developing osteoporosis, and includes all animals, including humans, monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits, or guinea pigs. By administering the pharmaceutical composition of this invention to these individuals, the said disease can be effectively prevented or treated. Furthermore, the pharmaceutical composition of this invention may exhibit a synergistic effect when administered in combination with existing therapeutic agents.
[0042] The term "administration" in this invention means providing a specific substance to a patient by any appropriate method, and the route of administration of the composition of this invention may be administered through any general route as long as it can reach the target tissue. It may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, locally, intranasally, intrapulmonaryly, or rectally, but is not limited thereto. Additionally, the pharmaceutical composition of this invention may be administered by any device capable of delivering the active substance to target cells. Preferred modes of administration and formulations include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, drip infusions, etc. Injectable preparations can be manufactured using aqueous solvents such as physiological saline solution and Ringer's solution, vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin), etc., and may include pharmaceutical carriers such as stabilizers to prevent deterioration (e.g., ascorbic acid, sodium bisulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers to adjust pH, and preservatives to inhibit microbial growth (e.g., phenylmercury nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.).
[0043] For example, the composition of the present invention may further include a pharmaceutically acceptable carrier, diluent, or excipient, and may be formulated and used in various forms according to conventional methods for each intended use, such as oral formulations like powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, and injectable formulations like sterile injectable solutions, and may be administered orally or through various routes including intravenous, intraperitoneal, subcutaneous, rectal, and local administration. Examples of suitable carriers, excipients, or diluents that may be included in such compositions include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, the composition of the present invention may further include fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, etc.
[0044] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are formulated by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., into the above composition. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc may be used.
[0045] Examples of oral liquid formulations include suspensions, liquid formulations, emulsions, syrups, etc., and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included.
[0046] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. As non-aqueous solvents and suspensions, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used. As bases for suppositories, Witepsol, Macrogol, Tween 61, cocoa oil, laurin oil, glycerogelatin, etc., may be used. Meanwhile, injectable preparations may contain conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifiers, stabilizers, and preservatives.
[0047] The above formulation may be prepared by conventional mixing, granulation, or coating methods and may contain an active ingredient in the range of about 0.1 to 75 weight%, preferably about 1 to 50 weight%. A unit formulation for a mammal weighing about 50 to 70 kg contains about 10 to 200 mg of the active ingredient.
[0048] At this time, the composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" in the present invention refers to an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects. The effective dose level may be determined based on factors including the patient's health status, type and severity of the disease, drug activity, sensitivity to the drug, method of administration, time of administration, route of administration and elimination rate, duration of treatment, drugs used in combination or concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above-mentioned factors into consideration, and this can be easily determined by a person skilled in the art.
[0049] For example, since the dosage may be increased or decreased depending on the route of administration, severity of the disease, gender, body weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0050] The preferred dosage of the compound of the present invention varies depending on the patient's condition and body weight, the severity of the disease, the form of the drug, the route of administration, and the duration, but can be appropriately selected by those skilled in the art. However, for a desirable effect, it is preferable to administer the compound of the present invention at a dose of 0.0001 to 100 mg / kg (body weight) per day, preferably 0.001 to 100 mg / kg (body weight). Administration may be administered once a day or in divided doses via oral or parenteral routes.
[0051] The composition for the prevention or treatment of osteoporosis of the present invention may be prepared into a pharmaceutical formulation using methods well known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal. In preparing the formulation, the active ingredient may be mixed or diluted with a carrier, or encapsulated within a carrier in the form of a container.
[0053] In addition, the present invention may provide a quasi-drug composition for the prevention or treatment of bone diseases comprising N-dodecyl-4-hydroxybenzamide (LSW04).
[0054] The term "quasi-drug" as used in the present invention refers to articles used for the purpose of diagnosing, treating, improving, alleviating, managing, or preventing diseases in humans or animals, among which the effect is milder than that of pharmaceuticals. For example, quasi-drugs under the Pharmaceutical Affairs Act are those excluding articles used for pharmaceutical purposes, and include products used for the treatment or prevention of diseases in humans or animals, and products that have a mild effect on the human body or do not act directly on it.
[0055] When the composition according to the present invention is used as an additive for quasi-drugs, the composition may be added as is or used together with other quasi-drugs or quasi-drug ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use. In addition, the quasi-drug may include a topical skin preparation, and said topical skin preparation may be manufactured and used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel, or gel, but is not limited thereto.
[0057] In addition, according to another aspect of the present invention, the present invention provides a food composition for the prevention or improvement of bone disease comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0058] The "improvement" of the present invention refers to any act of improving or benefiting the suspected symptoms of the target disease and the subject of the invention by using a composition comprising the compound of Formula 1 or a food-grade acceptable salt thereof.
[0059] In addition, the above-mentioned "food-grade acceptable salt" can be defined identically to the aforementioned pharmaceutically acceptable salt.
[0060] The above food composition includes compositions for all forms of food, such as health functional food, nutritional supplement, food additives, special medicinal food, and dietary supplement.
[0061] In the present invention, a health functional food refers to a group of foods to which added value has been imparted by using physical, biochemical, or biotechnological methods to make the functions of the food act or manifest for a specific purpose, or a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition.
[0062] The health functional food of the present invention includes forms such as tablets, capsules, pills, or liquids, and there are no particular limitations on the types of said health functional food. Examples may be any one selected from the group consisting of drinks, dairy products, confectionery, seasonings, beverages, snacks, candies, ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars, chocolate products, processed foods, grain products, pasta, soups, sauces and dressings, confectionery products, oils and fat products, dairy drinks, milk drinks, soy milk, soy dairy-like products, frozen foods, cooked foods, alternative foods, meat products, cheese, yogurt, bread, rolls, yeast products, cakes, cookies, and crackers, but are not limited thereto, and include all health foods in the conventional sense.
[0063] In the present invention, the food composition can be prepared by methods commonly used in the art, and the composition can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the food composition can also be prepared without limitation as long as it is a formulation recognized as a food composition.
[0064] Foods according to the present invention include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. In addition, foods include, but are not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.), and food additives. The above foods, beverages, or food additives may be manufactured by conventional manufacturing methods.
[0065] When the composition of the present invention is used as an additive to a health functional food, the composition may be added as is or used together with other health functional food ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to the purpose of use. Generally, when manufacturing food or beverages, the composition of the present invention may be added to the raw material in an amount preferably 50 parts by weight or less, more preferably 25 parts by weight or less. However, in the case of long-term consumption for the purpose of health control and hygiene, the above amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount greater than the above range.
[0066] In addition to containing the active ingredients of the present invention, the food or health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional food compositions. Examples of the above-mentioned natural carbohydrates are monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; and polysaccharides, such as conventional sugars like dextrin, cyclodextrin, etc.; and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The above-mentioned flavoring agents may advantageously include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).
[0067] In addition, the food composition may contain, in addition to the active ingredients of the present invention, various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages.
[0068] Since the active ingredient of the present invention can exhibit an effect of improving bone function through the inhibition of osteoclast formation, it can be usefully utilized, for example, as a health functional food for the elderly or as a health functional food for promoting growth in the growth stage. At the same time, it can be used as a special medicinal food for patients suffering from reduced bone function.
[0069] At this time, the above active ingredient may be used in the food composition of the present invention in an amount of 0.01 to 100 weight%. The above type of food composition may be prepared in various forms according to conventional methods known in the art. For example, as a health food, it may be prepared in the form of gum, vitamin complex, tea, juice, and drink containing the active ingredient, and the food composition having the active ingredient as an active ingredient may be consumed by granulating, encapsulating, or powdering it. The functional food composition of the present invention may include ingredients that are typically added during food manufacturing, and may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
[0070] For example, when manufactured as a drink, in addition to the active ingredients of the present invention, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, jujube extract, licorice extract, etc. may be additionally included.
[0071] The above food composition may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, it may contain extracts for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination.
[0072] In the case of long-term consumption for the purpose of health and hygiene or health control, the food composition of the present invention can be taken for a long period of time because there are no problems in terms of safety.
[0074] In addition, according to another aspect of the present invention, the present invention provides a veterinary composition for the prevention or treatment of bone disease comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0075] The veterinary composition according to the present invention may be administered according to a number of administration methods widely known in the art and may be adjusted to suit the treatment of each of these animals. These compositions may be in the form of a solution, or a suspension for oral administration or injection, or in a solid or semi-solid form, or in the form of a powder, capsule, granule, sugar-coated tablet, soft capsule, spray, caplet, pill, tablet, or paste. Depending on the formulation and drug, the veterinary composition may further include conventional pharmaceutical ingredients for preparing liquid or solid formulations to be administered orally or parenterally. In addition, in the case of formulations for oral administration, these formulations may be administered directly to animals and may be mixed into food, but are not limited thereto.
[0077] In addition, according to another aspect of the present invention, the present invention may provide a feed composition for preventing or improving bone disease comprising, as an active ingredient, a compound represented by the above-described formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0078] The above active ingredient can be prepared in the same way as in the case of the above pharmaceutical composition or food composition.
[0079] The feed composition of the present invention may be a feed additive or a compound feed.
[0080] The active ingredient of the present invention can exhibit an overall improvement effect due to the enhancement of bone function, so it may be included in a feed composition as a growth promoter for animals or livestock.
[0081] Specifically, the feed containing the active ingredient according to the present invention can be manufactured in various forms of feed known in the art, and preferably may include concentrated feed, roughage, or special feed.
[0082] Concentrated feeds include seed grains such as wheat, oats, and corn; bran, which is a byproduct obtained by refining grains and includes rice bran, wheat bran, and barley bran; oilseed meal, which is a byproduct obtained by extracting oil from soybeans, rapeseed, sesame, flaxseed, and coconut; residues such as residual starch, which is the main component of starch residue remaining after removing starch from sweet potatoes and potatoes; fish meal, fish residue; fish soluble, which is a concentrated fresh liquid obtained from fish; meat meal, blood meal, feather meal; skim milk powder; dried whey, which is the residue obtained when making cheese from milk and casein from skim milk; and animal feeds such as yeast, Chlorella, and seaweed.
[0083] Forage includes fresh fodder such as wild grass, pasture grass, and green cuts; root vegetables such as feed turnips, feed beets, and a type of turnip called lutebarger; silage, which is a stored feed made by filling a silo with fresh grass, green cut crops, and grains and fermenting them with lactic acid; hay made by cutting and drying wild grass and pasture grass; straw of livestock crops; and leaves of legumes.
[0084] Special feeds include mineral feeds such as shells and rock salt, urea feeds such as urea or its derivatives such as diuretic isobutane, feed additives and dietary supplements, which are substances added in small amounts to compound feed to supplement components that are prone to being lacking when only natural feed ingredients are mixed, or to improve the shelf life of the feed.
[0085] The feed composition according to the present invention may include various feed additives.
[0086] In the present invention, the term "feed additive" refers to a substance added to feed for the purpose of various effects, such as supplementing nutrients and preventing weight loss, improving the digestibility and utilization of fiber in the feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress during the summer. The feed additive of the present invention corresponds to an auxiliary feed under the Feed Management Act and may additionally include mineral preparations such as sodium bicarbonate (baking soda), bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamin preparations such as carotene, vitamin E, vitamins A, D, E, nicotinic acid, and vitamin B complex; protected amino acid preparations such as methionine and lysic acid; protected fatty acid preparations such as calcium salts of fatty acids; probiotics (lactic acid bacteria preparations); probiotics such as yeast cultures and mold fermentation products; and yeast preparations.
[0087] The feed composition according to the present invention is not particularly limited and can be applied to any individual intended for promoting overall bone function. The individual refers to animals, for example, non-primates (e.g., cattle, pigs, horses, cats, dogs, rats, and mice) and mammals including primates (e.g., monkeys, e.g., cynomolgous monkeys and chimpanzees). The individual is a livestock animal (e.g., horses, cattle, pigs, etc.) or a pet animal (e.g., dogs or cats).
[0088] The dosage of the feed composition according to the present invention will depend on a number of factors such as the animal's species, size, weight, and age. In principle, a typical dosage may be in the range of 0.001 to 10 g per animal / day, but is not limited thereto.
[0090] In addition, according to another aspect of the present invention, the present invention provides a medium composition for inhibiting the differentiation of osteoclasts comprising, as an active ingredient, a compound represented by the above-described chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof.
[0091] Since the composition of the present invention includes the above-described N-dodecyl-4-hydroxybenzamide (LSW04) as an active ingredient, the common details between the two are omitted to avoid excessive complexity in this specification. Effects of the invention
[0093] Since the composition of the present invention has an excellent effect of inhibiting the differentiation of bone marrow cells into osteoclasts that destroy or absorb bone tissue or inhibiting their activity, it can be usefully used as an active ingredient in a composition for the prevention or treatment of bone diseases, including osteoporosis. Brief explanation of the drawing
[0095] Figure 1 shows the drug analysis of LSW03 (control group) and LSW04 (experimental group) using osteoclast differentiation. Figure 2 shows the TRAP staining results of the LSW04 drug. Figure 3 shows the results of measuring the TRAP activity of the LSW04 drug. Figure 4 shows the results of the cell fusion analysis of the LSW drug. Figure 5 shows the results of the analysis of osteoclast differentiation and functional gene expression by the drug LSW04. Specific details for implementing the invention
[0096] The present invention will be described in more detail below through examples. These examples are intended solely to illustrate the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0098] Preparation Example 1: Preparation of Administration Drug
[0099] N-dodecyl-4-hydroxybenzamide (hereinafter LSW04), the drug to be administered, and N-dodecyl-2-hydroxybenzamide (hereinafter LSW03), the control, were synthesized by the convergent conformation method by Molecules & Materials (Room E3-303, Industry-Academic Cooperation Building, 141 Gajeong-ro, Yuseong-gu, Daejeon).
[0100] [Chemical Formula 1]
[0101]
[0102] [Chemical Formula 2]
[0103]
[0105] Preparation Example 2: Osteoclast Differentiation
[0106] Bone marrow cells from which red blood cells had been removed were obtained from the femur and tibia of mice (C57BL / 6). The bone marrow cells were differentiated by culturing them for 6 days under conditions of M-CSF (macrophage colony stimulating factor) and ODF (Osteoclast Differentiation Factor).
[0108] Example 1. Candidate Drug Selection
[0109] As a preliminary experiment to confirm the effect on osteoclast differentiation, the candidate drugs, the control group (LSW03) and the experimental group (LSW04), were treated during osteoclast differentiation induction using mouse bone marrow cells. As shown in Fig. 1, the control group (10 uM) did not inhibit differentiation into osteoclasts, but the experimental group showed excellent osteoclast differentiation inhibition ability even at 10 uM.
[0110] Accordingly, the drug LSW04 was selected as the active ingredient of the present invention, and LSW04 was used in the following examples.
[0112] Example 2. Analysis of the effects of LSW04 drug on osteoclast differentiation and activity
[0113] To analyze the effect of the drug LSW04 on osteoclast differentiation (generation), isolated bone marrow cells were treated with various concentrations of LSW04 and ODF under conditions and then stained with TRAP. As shown in Figure 2, it was confirmed that the bone marrow cells differentiated into multinucleated cells composed of dozens of cells. In contrast, cells treated with 10 uM of LSW04 exhibited an early differentiation morphology, while differentiation into osteoclasts was inhibited at concentrations of 20 and 30 uM.
[0114] In addition, as a result of measuring TRAP activity, as shown in Figure 3, the LSW04 drug significantly inhibited the activity of TRAP that occurs during the osteoclast differentiation process.
[0116] Example 3. Analysis of the effect of LSW04 drug on cell fusion
[0117] Young bone marrow cells of the macrophage lineage differentiate into osteoclasts under the influence of osteoclast differentiation factor (ODF); during the differentiation process, numerous cells fuse to become multinucleated cells (~tens of cells), which then attach to the surface of the bone, and acid (H + It dissolves bone by secreting ). To analyze the effect of the drug LSW04 on cell fusion during the differentiation process of bone marrow cells, isolated bone marrow cells were cultured after treatment with M-CSF (30 ng / ml) and ODF (100 ng / ml), and the efficacy was analyzed by calculating the number of multinucleated cells after culturing for 5 days with various concentrations of the drug LSW04.
[0118] As a result, as shown in Figure 4, bone marrow cells treated with ODF differentiated more than 700 cells from 3 to less than 10 cells, whereas the LSW04 drug showed results of less than 300 cells at 10 µM, less than 150 cells at 20 µM, and less than 30 cells at 30 µM (left graph). In addition, bone marrow cells treated with ODF differentiated more than 130 cells from more than 10 cells, whereas in the case of LSW04 drug treatment, about 10 osteoclasts were observed only at 10 µM, and differentiation was inhibited at concentrations of 20 and 30 µM (right graph).
[0119] In addition, as shown in Figure 5, the LSW04 drug significantly reduced the expression of osteoclast function genes (TRAP, c-Fos, NFATc1, OSCAR, Cathepsin K, c-Src) induced by ODF.
[0121] Based on the above results, it has been proven that the LSW04 drug of the present invention not only excellently inhibits osteoclast differentiation and generation by intervening in the differentiation process into osteoclasts induced by ODF and M-CSF, but also significantly inhibits the expression of genes necessary for osteoclast differentiation; therefore, the LSW04 drug can be utilized as a treatment for osteoporosis.
[0123] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
Claims
Claim 1 A pharmaceutical composition for the prevention or treatment of bone disease comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 2 A pharmaceutical composition for the prevention or treatment of bone disease according to claim 1, characterized in that the bone disease is one or more selected from the group consisting of osteoporosis, periprosthetic osteolysis, osteolysis caused by fatigue debris of implants, Paget's disease, osteomalacia, rickets, osteopenia, calcium dysregulation, metastatic bone cancer, inflammatory bone loss, endocrine disease or drug-induced secondary bone loss, and periodontal disease accompanied by destruction of alveolar bone. Claim 3 A pharmaceutical composition for the prevention or treatment of bone disease according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate reduces or inhibits differentiation into osteoclasts or the production of osteoclasts. Claim 4 A pharmaceutical composition for the prevention or treatment of bone disease according to claim 1, wherein the compound represented by Chemical Formula 1, its pharmaceutically acceptable salt, its hydrate, or its solvate inhibits the expression of one or more selected from the group consisting of TRAP (tartrate-resistant acid phosphatase), c-Fos (Proto-oncogene c-Fos), NFATc1 (Nuclear Factor of Activated T cells, cytoplasmic 1), OSCAR (osteoclast-associated receptor), cathepsin K, and c-Src (Proto-oncogene tyrosine-protein kinase Src). Claim 5 A food composition for the prevention or improvement of bone disease comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 6 A veterinary composition for the prevention or treatment of bone disease comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 7 A feed composition for the prevention or improvement of bone disease comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] . Claim 8 A medium composition for inhibiting the differentiation of osteoclasts comprising, as an active ingredient, a compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof: [Chemical Formula 1] .
